Revenue (Tables)

12 Months Ended

Dec. 31, 2023

Revenue

Schedule of revenue recognized from collaborative arrangements

	Year Ended December 31,
(In thousands)	2023		2022
Viatris collaboration agreement – Amounts receivable from Viatris	$	57,201	$	48,624
Viatris royalties (Non-US)		7		30
Total	$	57,208	$	48,654

	Year Ended December 31,
(In thousands)	2023		2022
YUPELRI net sales (Theravance Biopharma implied 35%)	$	77,337	$	70,653

Schedule of collaborative amounts were recorded in the Company's condensed consolidated statements of operations

	Year Ended December 31,
(In thousands)	2023		2022
Viatris	$	216	$	24
Other		—		168
Total collaboration revenue	$	216	$	192

Summary of the reductions to R&D costs related to reimbursement payments

	Year Ended December 31,
(In thousands)	2023		2022
Viatris	$	5,723	$	6,682